METHODS: This was a cross-sectional, observational study in which adult U.S. residents (aged 18+ years) with AD or caregivers of pediatric U.S. patients with AD (aged 0-17 years) completed an online survey (3 June-16 July 2021).
RESULTS: Respondents (N = 978) were primarily adults with AD (81.8%), female (67.7%), and white (70.2%). There were 645 insurance delays or denials for AD prescriptions, with 48.1% (470/978) of respondents experiencing at least one delay/denial in the past year. Most delays/denials were for topical steroids (39.2%, 253/645), the most highly used prescription treatment class (83.9%, 821/978). However, the highest rate of delay/denials was for biologics, of which 43.6% (109/250) of all prescriptions faced a delay or denial. Denials were caused primarily by step therapy (27.6%) and delays by prior authorization (55.1%). Only 56.0% of respondents said they would know what to do if they faced an issue with AD prescription coverage.
CONCLUSIONS: Patients with AD frequently experience insurance-related barriers to obtaining recommended therapies, and many do not know how to respond when these barriers arise. Strategies to improve timely therapeutic access are needed.
方法:这是一个横截面,在观察性研究中,美国成年AD患者(18岁以上)或美国儿科AD患者(0~17岁)的护理人员完成了一项在线调查(2021年6月3日至7月16日).
结果:受访者(N=978)主要是患有AD的成年人(81.8%),女性(67.7%),白色(70.2%)。有645次AD处方的保险延误或拒绝,48.1%(470/978)的受访者在过去一年中至少经历过一次延迟/拒绝。大多数延误/拒绝是局部类固醇(39.2%,253/645),使用最多的处方治疗类(83.9%,821/978)。然而,延迟/拒绝率最高的是生物制品,其中43.6%(109/250)的处方面临延迟或拒绝。拒绝主要由阶梯治疗(27.6%)和事先授权的延迟(55.1%)引起。只有56.0%的受访者表示,如果他们面临AD处方保险的问题,他们会知道该怎么做。
结论:AD患者在获得推荐治疗时经常会遇到保险相关障碍,当这些障碍出现时,许多人不知道如何应对。需要改进及时获得治疗的策略。